Pharming Total Current Assets from 2010 to 2026
| PHARM Stock | EUR 1.44 0.04 2.86% |
Total Current Assets | First Reported 2009-12-31 | Previous Quarter 245.8 M | Current Value 277.6 M | Quarterly Volatility 102.1 M |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.3 M, Interest Expense of 6.6 M or Selling And Marketing Expenses of 7.8 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.82. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming | Total Current Assets |
Analyzing Pharming Group's Total Current Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Current Assets has evolved provides context for assessing Pharming Group's current valuation and future prospects.
Latest Pharming Group's Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Pharming Group NV over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Pharming Group's Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Pharming Total Current Assets Regression Statistics
| Arithmetic Mean | 153,565,683 | |
| Geometric Mean | 100,034,044 | |
| Coefficient Of Variation | 76.30 | |
| Mean Deviation | 106,468,460 | |
| Median | 119,301,684 | |
| Standard Deviation | 117,169,203 | |
| Sample Variance | 13728.6T | |
| Range | 313.7M | |
| R-Value | 0.96 | |
| Mean Square Error | 1192.4T | |
| R-Squared | 0.92 | |
| Slope | 22,238,235 | |
| Total Sum of Squares | 219658T |
Pharming Total Current Assets History
About Pharming Group Financial Statements
Pharming Group stakeholders use historical fundamental indicators, such as Pharming Group's Total Current Assets, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharming Group's assets and liabilities are reflected in the revenues and expenses on Pharming Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharming Group NV. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Assets | 309.4 M | 324.8 M |
Thematic Opportunities
Explore Investment Opportunities
Check out the analysis of Pharming Group Correlation against competitors. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.